STOCK TITAN

Arrowhead Pharma - ARWR STOCK NEWS

Welcome to our dedicated page for Arrowhead Pharma news (Ticker: ARWR), a resource for investors and traders seeking the latest updates and insights on Arrowhead Pharma stock.

Arrowhead Pharmaceuticals Inc. (ARWR) is a clinical-stage biotechnology leader developing RNA interference (RNAi) therapies that target disease-causing genes. This page provides investors and industry professionals with verified updates on the company's progress in advancing treatments for genetic disorders through its proprietary TRIM™ delivery platform.

Access consolidated, factual reporting of Arrowhead's material developments including clinical trial milestones, regulatory submissions, research collaborations, and financial disclosures. Our news aggregation ensures efficient tracking of therapeutic advancements in hepatitis B, cardiovascular diseases, and rare genetic conditions.

All content undergoes strict verification to maintain compliance with financial reporting standards. For stakeholders monitoring RNAi innovation and precision medicine breakthroughs, this resource offers centralized access to essential updates without speculative commentary.

Bookmark this page for streamlined monitoring of Arrowhead's progress in developing targeted gene silencing therapies. Check regularly for authoritative reporting on pipeline developments and strategic initiatives shaping the future of RNA-based medicine.

Rhea-AI Summary

Arrowhead Pharmaceuticals (NASDAQ: ARWR) has received a $15 million milestone payment from Horizon Therapeutics (NASDAQ: HZNP) following the enrollment of the first subject in a Phase 1 clinical trial for HZN-457, aimed at treating gout. This candidate, previously known as ARO-XDH, targets liver xanthine dehydrogenase to lower uric acid levels. The study will enroll 56 healthy volunteers to assess safety, tolerability, and pharmacokinetics. The collaboration with Horizon is pivotal in advancing innovative treatments for the over 9 million gout patients in the U.S.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.96%
Tags
-
Rhea-AI Summary

Arrowhead Pharmaceuticals reported fiscal year 2022 results, achieving $243.2 million in revenue, up from $138.3 million in 2021. The company incurred a net loss of $172.7 million or $1.67 per diluted share. Operating expenses rose to $421.7 million compared to $287.3 million the prior year. Despite financial challenges, significant progress was made in clinical trials, with promising interim data on ARO-APOC3 and ARO-ANG3. The balance sheet was bolstered by a $250 million royalty sale and potential future earnings from Amgen.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.11%
Tags
-
Rhea-AI Summary

Arrowhead Pharmaceuticals (NASDAQ: ARWR) will hold a webcast and conference call on November 28, 2022, at 4:30 p.m. ET to discuss its financial results for the fiscal year ending September 30, 2022. Investors can access the live audio via the company’s website, with a replay available two hours post-call. Arrowhead focuses on developing RNA interference therapies targeting intractable diseases.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.78%
Tags
conferences earnings
Rhea-AI Summary

Arrowhead Pharmaceuticals has announced that Royalty Pharma has acquired a royalty interest in Amgen's olpasiran for $250 million upfront, plus up to $160 million in additional payments based on milestones. Olpasiran, developed for cardiovascular disease treatment, is approaching Phase 3 trials. Arrowhead retains rights to $400 million in milestone payments related to Amgen's development of olpasiran. This agreement reinforces the potential of olpasiran and supports Arrowhead's investment in its RNAi therapeutic pipeline.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.53%
Tags
none
-
Rhea-AI Summary

Arrowhead Pharmaceuticals presented new clinical data on RNAi-based therapies ARO-APOC3, ARO-ANG3, and olpasiran at the AHA Scientific Sessions 2022. ARO-APOC3 showed significant decreases in triglycerides by 86% and increases in HDL-C by 99%. ARO-ANG3 reduced triglycerides by 59% and LDL-C by 32%, while olpasiran decreased lipoprotein(a) levels by over 95% in ASCVD patients. The company plans to discuss these findings and its future plans in a virtual event on November 9, 2022.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.94%
Tags
-
Rhea-AI Summary

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) announced on October 4, 2022, the approval of inducement grants for 39 new employees, totaling up to 117,500 restricted stock units. This includes 30,000 restricted stock units awarded to Peter Carignan, the new vice president of clinical operations. The grants, which fall under NASDAQ Listing Rules, are outside existing shareholder-approved equity incentive plans and will vest over four years.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.93%
Tags
none
Rhea-AI Summary

Arrowhead Pharmaceuticals (NASDAQ: ARWR) will present interim clinical data on ARO-APOC3 and ARO-ANG3 at the American Heart Association Scientific Sessions 2022 in Chicago, from November 5-7, 2022. The SHASTA-2 and ARCHES-2 Phase 2 studies focus on patients with severe hypertriglyceridemia and mixed dyslipidemia, respectively. A virtual investor event is scheduled for November 9, 2022, to discuss these findings and future developments. Full data from ARCHES-2 is expected in the first half of 2023.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.49%
Tags
conferences clinical trial
-
Rhea-AI Summary

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) will participate in several upcoming events in September 2022. Key presentations include:

  • ERS International Congress: September 4-6, 2022, by Erik Bush on MMP7 gene silencing.
  • Wells Fargo Healthcare Conference: September 7-9, 2022, investor meetings with Vincent Anzalone.
  • H.C. Wainwright Global Investment Conference: September 12-14, 2022, fireside chat by Christopher Anzalone.
  • Baird Global Healthcare Conference: September 13-14, 2022, also featuring Christopher Anzalone.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.98%
Tags
conferences
-
Rhea-AI Summary

Arrowhead Pharmaceuticals (NASDAQ: ARWR) has submitted an application to commence a Phase 1/2a clinical trial for ARO-MMP7, an investigational RNA interference therapeutic targeting matrix metalloproteinase 7 (MMP7) for idiopathic pulmonary fibrosis (IPF). The trial aims to assess safety, tolerability, and pharmacokinetics in healthy volunteers and IPF patients. This initiative expands Arrowhead's clinical pipeline, which includes other lung disease candidates. The trial approval is pending from the local Ethics Committee and the New Zealand Medicines and Medical Devices Safety Authority.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.67%
Tags
Rhea-AI Summary

Arrowhead Pharmaceuticals (NASDAQ: ARWR) announced its fiscal Q3 results for the period ending June 30, 2022, revealing a revenue of $32.4 million, down from $45.9 million in Q3 2021. The operating loss increased to $72.9 million, compared to $31.9 million the previous year. Notably, the company published promising Phase 2 clinical results for fazirsiran, with 58% of patients showing fibrosis regression. Arrowhead also initiated clinical studies for ARO-MUC5AC and ARO-RAGE and expanded its team. Cash resources stand at $582.4 million.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.37%
Tags
Arrowhead Pharma

Nasdaq:ARWR

ARWR Rankings

ARWR Stock Data

1.66B
119.34M
13.2%
74.66%
6.7%
Biotechnology
Pharmaceutical Preparations
Link
United States
PASADENA